Clinical Trial Search

Primary: Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD) — 24; 57 percentage of participants — p=.036

Primary: The Maximum Observed Concentration of Midazolam After a Single Dose of Brodalumab — 11.5 nanograms per milliliter

Primary: Number of Participants With Adverse Events — 3; 6; 4; 6 Participants

Primary: Amount of Drug Consumed Per Hour in Each Group(Arm) — 16.2; 14.6; 15.3; 16 milliliters per hour

Primary: Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) — 122.0; 130.2; 120.2; 124.2 mmHg

Primary: Change From Baseline in Time-weighted Average Over 24 Hours Post Dose (TWA [0-24]) in Systolic Blood Pressure (SBP) — -9.5; -10.2; -4.8; -2.8 mmHg

Primary: Adverse Events — 1 participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 1; 1; 2; 1 Participants

Primary: Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977. — -0.545…

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 9; 7; 5 participants

Primary: Count of Participants With Blisters — 8; 47; 35 Participants

Primary: Safety and Tolerability of AZD9977 by Assessing the Percentage of Participants With Adverse Events — 43.8; 16.7; 33.3; 33.3 percentage of participants

Primary: Number of Participants With Adverse Events up to 210 Days After Vaccination — 9; 9; 9; 9 participants

Primary: Number of Participants With Sufficient Vitamin D Levels (≥30 ng/ml) After 8 Weeks of Supplementation — 8; 6; 4 participants

Primary: Number of Participants Experiencing an Adverse Event — 2; 2; 4; 1 Participants